Antibody responses to pneumococcal polysaccharide vaccine in Taiwanese patients with chronic obstructive pulmonary disease

Journal of the Formosan Medical Association

Volumn 106, Issue 3, 2007, Pages 196-203

  Lai, Chih Cheng ^a,b   Lee, Li Na ^b   Yu, Chong Jen ^b   Hseuh, Po Ren ^b   Yang, Pan Chyr ^b   Kuo, Sow Hsong ^b   Luh, Kwen Tay ^b  

^a LOTUNG POH AI HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antibody response; Chronic obstructive pulmonary disease; Pneumococcal polysaccharide vaccine

Indexed keywords

IMMUNOGLOBULIN G; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG INDICATION; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; SEROTYPE; TAIWAN; TREATMENT OUTCOME; VACCINATION;

EID: 34247509403     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60240-0     Document Type: Article

References (27)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause: 1990-2020 Global Burden of Disease Study. Lancet 1997;349:1498-504.
2. Seemungal TA, Donaldson GC, Bhowmilk A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
3. Siu LK, Chu ML, Ho M, et al. Epidemiology of invasive pneumococcal infection in Taiwan; antibiotic resistance, serogroup distribution and ribotype analysis. Microb Drug Resist 2002;8:201-8.
4. Örtqvist A, Hedlund J, Grillner, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J 1990;3:1105-13.
5. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993; 137:977-88.
6. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-408.
7. Hsueh PR, Luh KT. Antimicrobial resistance in Streptococcus pneumoniae, Taiwan. Emerg Infect Dis 2002;8:1487-91.
8. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46:1-24.
9. Wright AE, Morgan W, Colbrook L, et al. Observations on prophylactic inoculations against pneumococcus infection, and on the results which have been achieved by it. Lancet 1914;1:1-10, 87-95.
10. Maynard GD. An inquiry into the etiology, manifestations and prevention of pneumonia amongst natives on the Rand from tropical area. Publ S Afr Inst Med Res 1913; 1:1-101.
11. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumonia in the United States. N Engl J Med 2000;343:1917-24.
12. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
13. Butler JC, Shapiro ED, Carlone GM. Pneumococcal vaccine: history, current status and further direction. Am J Med 1999;107:69-76.
14. Farr BM, Johnston BL, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk. Results of a match case-control study. Arch Intern Med 1995;155:2336-40.
15. Koivula I, Sten M, Leinonen M, et al. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-base trial. Am J Med 1997;103:281-90.
16. Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998;351:399-403.
17. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia people. JAMA 1997;278:1333-9.
18. Nichol KL, Baken L, Wuorenma J, et al. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999;159:2437-42.
19. Ament A, Baltussen R, Dura G, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 2000;31: 444-50.
20. Davidson ML, Bulkow LR, Grabman J, et al. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med 1994;154:2209-14.
21. Carson PJ, Nichol KL, O'Brien J, et al. Immune function and vaccine responses in healthy advanced elderly patients. Arch Intern Med 2000;160:2017-24.
22. Musher DM, Groover JE, Rowland J, et al. Antibody to capsular polysaccharides of Streptococcus; pneumonia: prevalence, persistence, and response to revaccination. Clin Infect Dis 1993;17:66-73.
23. Snakilampi U, Honkanen PO, Bloigu A, et al. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1996;173:387-93.
24. Bogaert D, Valk PV, Ramdin R, et al. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect Immun 2004; 72:818-23.
25. Lottenbach KR, Mink CM, Barenkamp SJ, et al. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect Immun 1999; 67:4935-8.
26. Fung CP, Hu BS, Lee SC, et al. Antimicrobial resistance of Streptococcus pneumoniae isolated in Taiwan: an island-wide surveillance study between 1996 and 1997. J Antimicrob Chemother 2000;45:49-55.
27. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin Microbial Rev 2003; 15:308-18.